摘要
目的:分析康艾注射液用于子宫颈癌术后同步放化疗中的临床效果及对患者血清胰岛素样生长因子-2(IGF-2)、鳞状细胞癌抗原(SCC)、干扰素-γ(IFN-γ)水平的影响。方法:选择我院2014年8月~2016年8月收治的102例子宫颈癌患者,依据抽签法分为对照组与研究组,每组各51例。两组均行腹腔镜宫颈癌切除术,对照组于术后采用同步放化疗,研究组基于对照组加以康艾注射液治疗。比较两组的临床疗效,治疗前后血清IGF-2、SCC、IFN-γ水平,NK细胞、CD3^+、CD4^+、CD8^+、CD4^+/CD8^+以及不良反应的发生情况。结果:治疗后,研究组总有效率显著高于对照组(P<0.05)。治疗后,两组血清IGF-2、SCC、IFN-γ水平、CD8^+均较治疗前显著降低,且研究组以上指标显著低于对照组;两组NK细胞、CD3^+、CD4^+均较治疗前明显上升,且研究组以上指标显著高于对照组,差异均有统计学意义(P<0.05)。研究组不良反应的发生率明显低于对照组(P<0.05)。结论:康艾注射液用于子宫颈癌术后同步放化疗的临床效果确切,且能够显著降低患者血清IGF-2、SCC、IFN-γ水平并改善患者的免疫功能。
Objective:To analyze the clinical effects of Kang'ai injection on cervical cancer postoperative chemoradiation and the serum levels of insulin-like growth factor 2(IGF-2),squamous cell carcinoma antigen(SCC) and interferon-γ(IFN-γ).Methods:102 cases with cervical cancer who were treated in our hospital from August 2014 to August 2016 were selected and randomly divided into the control group and the research group with 51 cases in each group.The patients in the control group were treated with concurrent chemoradiation and chemotherapy,while the patients in the research group were treated with Kang'ai injection on the basis of control group.Then the clinical curative effect,serum levels of IGF-2,SCC,IFN-γ,NK cells,CD3+,CD4+,CD8+and CD4+/CD8+ and the incidence of adverse reactions were observed and compared between two groups before and after the treatment.Results:The total effective rate of research group was higher than that of the control group(P〈0.05).After treatment,the serum levels of IGF-2,SCC,IFN-γ and CD8+ in both groups were decreased,which were lower in the research group than those of the control group(P〈0.05).After treatment,the levels of NK cells,CD3+ and CD4+ in both groups were increased,which were higher in the research group than those of the control group(P〈0.05).The incidence of adverse reactions in the research group was lower than that of the control group(P〈0.05).Conclusion:Kang'ai injection could effectively reduce the serum levels of IGF-2,SCC and IFN-γ,and improve the immune functions of patients with cervical cancer postoperative chemoradiation.
作者
王晋
王月玲
谭宏伟
米阳
刘丹
WANG Jin;WANG Yue-ling;TAN Hong-wei;MI Yang;LIU Dan(Department of Obstetrics and Gynecology,northwest women and children's Hospital,Xi'an,Shaanxi,710054,China;Department of Obstetrics and Gynecology,the First Affiliated Hospital of Xi'an Jiao Tong University,Xi'an,Shaanxi,710061,China)
出处
《现代生物医学进展》
CAS
2018年第18期3510-3513,共4页
Progress in Modern Biomedicine
基金
陕西省自然科学基金项目(9K0569)
关键词
子宫颈癌
康艾注射液
同步放化疗
胰岛素样生长因子-2
鳞状细胞癌抗原
干扰素-γ
Cervical cancer
Kang'ai injection
Concurrent chemoradiotherapy
Insulin-like growth factor 2
Squamous cell carcinomaantigen
Interferon-γ